Expecting More for Drug Discovery and Development

Pediatric Oncology

Why Pediatric Oncology Needs Its Own Drug Development Paradigm

David Alvaro, Ph.D.

Pharma's Almanac

Development CDMO

The Case for Earlier CDMO Involvement in Drug Development

David Alvaro, Ph.D.

Pharma's Almanac

Biologics

Commercial Thinking Begins in Clinical Phases

Mathias Kahl

IDT Biologika

Lipase Risk

An Integrated Analytical Approach to Lipase Risk Management in Biologics Development

Kyeyeon Hur, Ph.D.; Jimin Kim, Ph.D.; Minjeong Lee; Soojeong Oh; Woojung Jun

Samsung Biologics

MPS

What Will It Take for Organ-on-Chip Data to Replace Animal Studies?

David Alvaro, Ph.D.

Pharma's Almanac

Chinese Biopharma

Pharmaceutical Innovation in China Takes Center Stage

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Potency Assurance

Why Potency Cannot Be Reduced to a Release Assay in Active Immunotherapy Development

David Alvaro, Ph.D.

Pharma's Almanac

Preparedness

Preparing Manufacturing Networks for the Next Pandemic

Pharma's Almanac

Prevention

Preventive Therapeutics Beyond Vaccines

David Alvaro, Ph.D.

Pharma's Almanac

Mucosal Vaccine

Mucosal Vaccination and the Quest for Better Immunity

David Alvaro, Ph.D.

Pharma's Almanac

Masked Antibody

Expanding the Oncology Therapeutic Window Through Masked Antibody Technology

Sean McCarthy, Ph.D; David Alvaro, Ph.D.

CytomX Therapeutics

Vaccine Development

New Vaccine Technologies Expand the Frontiers of Prevention and Treatment

Cynthia A. Challener, Ph.D.

Pharma's Almanac